Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Psychiatry Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Psychiatry Other
    FDA Requests Boxed Warnings on Conventional Antipsychotic Drugs - (DGNews)
    Pramlintide-Related Improvements in Diabetes Benefit Patients' Psyche: Presented at ADA - (DGDispatch)
    Health Canada Approves New Treatment for Bipolar Mania - (DGNews)
    Report Confirms Increased Risk of Smoking, Substance Abuse in Bipolar Adolescents - (DGNews)
    Short-Term Antipsychotics in Older Adults With Dementia Associated With Serious Adverse Events - (DGNews)

    News archive

     Recent webcasts/CME - Psychiatry Other
    • Dementia in Hispanic Americans: The Reasons Behind the Risk
    • Prevalence and Associated Factors for Suicidal Ideation and Behaviors in Obsessive-Compulsive Disorder
      Delirium Update
      The Pharmacist's Role in Breaking the Cycle of PMDD
      Understanding Autism: The Role of the Pharmacist in the Management of Autism

      Webcasts/CME archive

       Recent cases - Psychiatry Other
        Factitious Lymphoedema as a Psychiatric Condition Mimicking Reflex Sympathetic Dystrophy: A Case Report
        Topiramate-Induced Psychosis in Two Members of the One Family: A Case Report
        Childhood Autism in a 13 Year Old Boy with Oculocutaneous Albinism: A Case Report
        Unexpected Depletion in Plasma Choline and Phosphatidylcholine Concentrations in a Pregnant Woman with Bipolar Affective Disorder Being Treated with Lithuim, Haloperidol and Benztropine: A Case Report
        Recognizing Thyrotoxicosis in a Patient with Bipolar Mania: A Case Report

        Cases archive
          




        my personal edition > psychiatry other > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Mirtazapine-Amitriptyline Combination Warrants Caution

        A DGReview of :"Mirtazapine in combination with amitriptyline: a drug-drug interaction study in healthy subjects"
        Human Psychopharmacology: Clinical and Experimental

        03/12/2003
        By David Loshak


        Combined daily administration of the noradrenergic/serotonergic enhancer mirtazapine and the tricyclic anti-depressant amitriptyline alters their pharmacokinetics only slightly but, the combination should be used with caution, say researchers in Oss, the Netherlands.

        Adding one drug to the other or substituting one for the other had no major effects on tolerability, they added.

        The researchers assessed both the steady-state pharmacokinetics of the two agents together compared with each alone, and their tolerability and effects on psychometric tests of acute and sub-chronic administration, also together or alone. Twelve healthy men and women were assigned to six different sequences of three 9-day treatments. A placebo group of four men and four women were studied as well, during the first treatment period to control for acute pharmacodynamic assessments.

        Serial blood samples were drawn for plasma level measurements and pharmacokinetic analysis. Psychometric tests assessed performance. Computer-assisted telephone questionnaires assessed self-ratings of drowsiness, alertness and sleep quality.

        Amitriptyline increased the Cmax of mirtazapine by a significant 36% in men but not women. Mirtazapine significantly altered the Cmax of amitriptyline in both sexes, increasing it by 23% in men and lowering it by 23% in women. There were no other changes in pharmacokinetic parameters. Metabolite parameters were not affected either.

        Changes in parent compound levels resulted mainly from effects on absorption. Psychometric test results did not disclose any significant differences between combined and single drug treatments.

        The questionnaires did not disclose any clinically relevant differences between the active treatments.
        Human Psychopharmacology: Clinical and Experimental 2003;18:2:91-101. "Mirtazapine in combination with amitriptyline: a drug-drug interaction study in healthy subjects"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send